Eisai launches two products in Japan

6 July 2020

Shares of Eisai (TYO: 4523) edged up 1.1% to 8,615 yen by close of trading today, after the Japanese pharma revealed it has launched two products on the domestic market.

Firstly, Eisai launched its in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) 2.5mg, 5mg, 10mg tablets for treatment of insomnia. Eisai received marketing and manufacturing approval for this formulation on January 23, 2020, and the product was added to Japan’s National health Insurance drug price list on April 22, 2020.

Dayvigo was launched in the USA last month, following regulatory approval there in December 2019. In the USA, the drug competes with Merck & Co’s (NYSE: MRK) Belsomra (suvorexant), which has been approved since 2014and recorded sales of $306 million in 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK